应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ABEO Abeona Therapeutics Inc
盘后交易 03-26 17:30:54 EDT
4.33
-0.09
-2.04%
盘后
4.33
+0.00
0.00%
16:10 EDT
最高
4.41
最低
4.28
成交量
128.14万
今开
4.36
昨收
4.42
日振幅
2.94%
总市值
2.47亿
流通市值
1.84亿
总股本
5,705万
成交额
553.95万
换手率
3.01%
流通股本
4,260万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Abeona Therapeutics 全年营运收入为-8944.8万美元,远逊于Ibes预估的-7840万美元
美股速递 · 03-17
Abeona Therapeutics 全年营运收入为-8944.8万美元,远逊于Ibes预估的-7840万美元
Abeona Therapeutics Inc:Zevaskyn 额外活检计划于本季度剩余时间进行
美股速递 · 03-09
Abeona Therapeutics Inc:Zevaskyn 额外活检计划于本季度剩余时间进行
Abeona Therapeutics® 公布业务进展,Zevaskyn® 商业上市势头持续增强
美股速递 · 03-09
Abeona Therapeutics® 公布业务进展,Zevaskyn® 商业上市势头持续增强
Abeona Therapeutics第三季度运营收入为-2401.8万美元,低于Ibes预期的-1820万美元
美股速递 · 2025-11-12
Abeona Therapeutics第三季度运营收入为-2401.8万美元,低于Ibes预期的-1820万美元
Abeona Therapeutics® 任命 James A. Gow 博士担任临床开发与医学事务高级副总裁
美股速递 · 2025-10-20
Abeona Therapeutics® 任命 James A. Gow 博士担任临床开发与医学事务高级副总裁
Abeona Therapeutics宣布其治疗X连锁视网膜劈裂症的Abo-503基因疗法入选FDA罕见疾病终点推进试点项目
美股速递 · 2025-10-13
Abeona Therapeutics宣布其治疗X连锁视网膜劈裂症的Abo-503基因疗法入选FDA罕见疾病终点推进试点项目
Abeona Therapeutics Inc.盘中异动 大幅下跌5.04%报5.38美元
市场透视 · 2025-10-10
Abeona Therapeutics Inc.盘中异动 大幅下跌5.04%报5.38美元
Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%
市场透视 · 2025-03-05
Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%
Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。
金融界 · 2025-03-05
Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。
Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元
市场透视 · 2025-01-28
Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元
Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元
市场透视 · 2024-11-27
Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元
Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元
市场透视 · 2024-09-30
Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元
加载更多
公司概况
公司名称:
Abeona Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Abeona Therapeutics, Inc.于1974年在怀俄明州注册成立。该公司是一家处于商业阶段的生物制药公司,为危及生命的疾病开发细胞和基因疗法。2025年4月28日,美国食品药品监督管理局批准了ZEVASKYN(prademagene zamikeracel)基因修饰的细胞片,作为第一种也是唯一一种基于自体细胞的基因疗法,用于治疗成人和儿童RDEB患者的伤口,RDEB是一种严重且令人衰弱的遗传性皮肤病。RDEB无法治愈,ZEVASKYN是唯一一种经美国食品药品监督管理局批准的产品,可以一次性治疗RDEB伤口。ZEVASKYN被美国食品药品监督管理局授予孤儿药和罕见儿科疾病名称。
发行价格:
--
{"stockData":{"symbol":"ABEO","market":"US","secType":"STK","nameCN":"Abeona Therapeutics Inc","latestPrice":4.33,"timestamp":1774555200000,"preClose":4.42,"halted":0,"volume":1281393,"hourTrading":{"tag":"盘后","latestPrice":4.33,"preClose":4.33,"latestTime":"16:10 EDT","volume":4538,"amount":19649.5091416,"timestamp":1774555804986,"change":0,"changeRate":0,"amplitude":0.006859},"delay":0,"changeRate":-0.020361990950226214,"floatShares":42603300,"shares":57049023,"eps":1.01,"marketStatus":"盘后交易","change":-0.09,"latestTime":"03-26 17:30:54 EDT","open":4.36,"high":4.41,"low":4.28,"amount":5539478.988873,"amplitude":0.029412,"askPrice":4.69,"askSize":1015,"bidPrice":4.1,"bidSize":20,"shortable":3,"etf":0,"ttmEps":1.01,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.42,"preHourTrading":{"tag":"盘前","latestPrice":4.38,"preClose":4.42,"latestTime":"09:28 EDT","volume":2405,"amount":10620.929735,"timestamp":1774531681016,"change":-0.04,"changeRate":-0.00905,"amplitude":0.027149},"postHourTrading":{"tag":"盘后","latestPrice":4.33,"preClose":4.33,"latestTime":"16:10 EDT","volume":4538,"amount":19649.5091416,"timestamp":1774555804986,"change":0,"changeRate":0,"amplitude":0.006859},"volumeRatio":0.851644,"impliedVol":0.2699,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/ABEO","defaultTab":"news","newsList":[{"id":"1195372622","title":"Abeona Therapeutics 全年营运收入为-8944.8万美元,远逊于Ibes预估的-7840万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195372622","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195372622?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:31","pubTimestamp":1773747071,"startTime":"0","endTime":"0","summary":"生物技术公司Abeona Therapeutics Inc公布的最新财务数据显示,其全年营运收入录得-8944.8万美元。这一表现显著低于市场研究机构Ibes此前预估的-7840万美元,凸显出公司在实现盈利方面仍面临挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"1127779905","title":"Abeona Therapeutics Inc:Zevaskyn 额外活检计划于本季度剩余时间进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1127779905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127779905?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:33","pubTimestamp":1773055992,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc 宣布,针对其研究性疗法 Zevaskyn 的额外活检计划已安排在本季度剩余时间内完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"1108449306","title":"Abeona Therapeutics® 公布业务进展,Zevaskyn® 商业上市势头持续增强","url":"https://stock-news.laohu8.com/highlight/detail?id=1108449306","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108449306?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:31","pubTimestamp":1773055916,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc 近期发布了业务更新,重点强调了其基因疗法 Zevaskyn® 在商业上市过程中不断积累的积极势头。公司表示,相关准备工作正在稳步推进,市场初步反馈良好,为后续的商业化成功奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"gpt_icon":0},{"id":"1115322918","title":"Abeona Therapeutics第三季度运营收入为-2401.8万美元,低于Ibes预期的-1820万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115322918","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115322918?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:32","pubTimestamp":1762950738,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics第三季度的运营收入为-2401.8万美元,而Ibes的预期为-1820万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"1174241986","title":"Abeona Therapeutics® 任命 James A. Gow 博士担任临床开发与医学事务高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1174241986","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174241986?lang=zh_cn&edition=full","pubTime":"2025-10-20 20:31","pubTimestamp":1760963478,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics® 任命 James A. Gow 博士为临床开发及医学事务的高级副总裁,负责相关业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"1120146347","title":"Abeona Therapeutics宣布其治疗X连锁视网膜劈裂症的Abo-503基因疗法入选FDA罕见疾病终点推进试点项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1120146347","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120146347?lang=zh_cn&edition=full","pubTime":"2025-10-13 19:30","pubTimestamp":1760355017,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics公司宣布,其针对X连锁视网膜劈裂症(XLRS)的Abo-503基因疗法已被美国食品药品监督管理局(FDA)选中,纳入罕见疾病终点推进(RDEA)试点项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"gpt_icon":0},{"id":"2574550364","title":"Abeona Therapeutics Inc.盘中异动 大幅下跌5.04%报5.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574550364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574550364?lang=zh_cn&edition=full","pubTime":"2025-10-10 23:01","pubTimestamp":1760108519,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日23时01分,Abeona Therapeutics Inc.股票出现异动,股价快速跳水5.04%。截至发稿,该股报5.38美元/股,成交量30.8826万股,换手率0.60%,振幅5.44%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.63%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010230159a6b32a42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010230159a6b32a42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABEOW","BK4539","BK4007","ABEO","LENZ","BK4139"],"gpt_icon":0},{"id":"2517260910","title":"Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517260910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517260910?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185145,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分,Abeona Therapeutics Inc.股票出现异动,股价大幅拉升5.13%。截至发稿,该股报5.33美元/股,成交量6506股,换手率0.01%,振幅0.00%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.20%。其相关个股中,Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃,换手率分别为342.41%、257.25%、186.62%,振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.,振幅分别为23.90%、13.51%、13.21%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223225abe9b0fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223225abe9b0fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABEOW","LENZ","ABEO"],"gpt_icon":0},{"id":"2517926917","title":"Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926917","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517926917?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:04","pubTimestamp":1741183446,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05220448547630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","ABEO"],"gpt_icon":0},{"id":"2506304699","title":"Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506304699?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:05","pubTimestamp":1737993938,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日00时05分,Abeona Therapeutics Inc.股票出现波动,股价大幅拉升5.23%。截至发稿,该股报5.54美元/股,成交量9.3329万股,换手率0.21%,振幅5.29%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.84%。其相关个股中,Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大,Onconetix, Inc.、Dogwood Therapeutics, Inc.、Evaxion Biotech As较为活跃,换手率分别为1969.92%、456.49%、218.44%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为86.84%、85.35%、65.16%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280005389612481b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280005389612481b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABEOW","LENZ","ABEO","BK4139"],"gpt_icon":0},{"id":"2486087345","title":"Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486087345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486087345?lang=zh_cn&edition=full","pubTime":"2024-11-27 23:08","pubTimestamp":1732720109,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日23时08分,Abeona Therapeutics Inc.股票出现异动,股价快速拉升5.14%。截至发稿,该股报6.34美元/股,成交量7.1051万股,换手率0.16%,振幅4.89%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.38%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127230830abe37c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127230830abe37c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ABEOW","ABEO","BK4139"],"gpt_icon":0},{"id":"2471638995","title":"Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471638995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471638995?lang=zh_cn&edition=full","pubTime":"2024-09-30 22:08","pubTimestamp":1727705304,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日22时08分,Abeona Therapeutics Inc.股票出现波动,股价大幅上涨5.26%。截至发稿,该股报6.20美元/股,成交量7.7815万股,换手率0.18%,振幅5.26%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.11%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930220824ab672922&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930220824ab672922&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ABEOW","BK4139","ABEO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abeonatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":-0.1467},{"period":"3month","weight":-0.183},{"period":"6month","weight":-0.1875},{"period":"1year","weight":-0.116},{"period":"ytd","weight":-0.1613}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abeona Therapeutics, Inc.于1974年在怀俄明州注册成立。该公司是一家处于商业阶段的生物制药公司,为危及生命的疾病开发细胞和基因疗法。2025年4月28日,美国食品药品监督管理局批准了ZEVASKYN(prademagene zamikeracel)基因修饰的细胞片,作为第一种也是唯一一种基于自体细胞的基因疗法,用于治疗成人和儿童RDEB患者的伤口,RDEB是一种严重且令人衰弱的遗传性皮肤病。RDEB无法治愈,ZEVASKYN是唯一一种经美国食品药品监督管理局批准的产品,可以一次性治疗RDEB伤口。ZEVASKYN被美国食品药品监督管理局授予孤儿药和罕见儿科疾病名称。","yearOnYearQuotes":[{"month":1,"riseRate":0.090909,"avgChangeRate":-0.103016},{"month":2,"riseRate":0.636364,"avgChangeRate":0.111579},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.010294},{"month":4,"riseRate":0.7,"avgChangeRate":0.022294},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010507},{"month":6,"riseRate":0.3,"avgChangeRate":0.003162},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.015738},{"month":8,"riseRate":0.636364,"avgChangeRate":0.073309},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.009981},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.003904},{"month":11,"riseRate":0.454545,"avgChangeRate":0.087228},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.137446}],"exchange":"NASDAQ","name":"Abeona Therapeutics Inc","nameEN":"Abeona Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abeona Therapeutics Inc(ABEO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abeona Therapeutics Inc(ABEO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abeona Therapeutics Inc,ABEO,Abeona Therapeutics Inc股票,Abeona Therapeutics Inc股票老虎,Abeona Therapeutics Inc股票老虎国际,Abeona Therapeutics Inc行情,Abeona Therapeutics Inc股票行情,Abeona Therapeutics Inc股价,Abeona Therapeutics Inc股市,Abeona Therapeutics Inc股票价格,Abeona Therapeutics Inc股票交易,Abeona Therapeutics Inc股票购买,Abeona Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abeona Therapeutics Inc(ABEO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abeona Therapeutics Inc(ABEO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}